系统性硬皮病的皮肤、肺和肠道微生物组的综述和路线图。
A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.
机构信息
Yale School of Medicine, Department of Medicine Section of Rheumatology, Allergy & Immunology, New Haven, CT, USA.
出版信息
Rheumatology (Oxford). 2021 Dec 1;60(12):5498-5508. doi: 10.1093/rheumatology/keab262.
Abstract
As our understanding of the genetic underpinnings of SSc increases, questions regarding the environmental trigger(s) that induce and propagate SSc in the genetically predisposed individual emerge. The interplay between the environment, the immune system, and the microbial species that inhabit the patient's skin and gastrointestinal tract is a pathobiological frontier that is largely unexplored in SSc. The purpose of this review is to provide an overview of the methodologies, experimental study results and future roadmap for elucidating the relationship between the SSc host and his/her microbiome.
摘要
随着我们对 SSc 的遗传基础的理解不断增加，出现了关于在遗传易感性个体中诱导和传播 SSc 的环境触发因素的问题。环境、免疫系统以及居住在患者皮肤和胃肠道中的微生物物种之间的相互作用是一个在 SSc 中基本上尚未探索的病理生物学前沿。本文的目的是提供一种方法学概述，介绍阐明 SSc 宿主与其微生物组之间关系的实验研究结果和未来路线图。
相似文献
1
A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.系统性硬皮病的皮肤、肺和肠道微生物组的综述和路线图。
Rheumatology (Oxford). 2021 Dec 1;60(12):5498-5508. doi: 10.1093/rheumatology/keab262.
2
Update on the Gastrointestinal Microbiome in Systemic Sclerosis.系统性硬化症胃肠道微生物组的最新研究进展。
Curr Rheumatol Rep. 2018 Jun 25;20(8):49. doi: 10.1007/s11926-018-0758-9.
3
Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement.系统性硬化症患者有和无胃肠道受累临床表现的肠道微生物群特征。
Sci Rep. 2017 Nov 1;7(1):14874. doi: 10.1038/s41598-017-14889-6.
4
The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.系统性硬化症中的微生物组：发病机制与治疗潜力。
Int J Mol Sci. 2022 Dec 18;23(24):16154. doi: 10.3390/ijms232416154.
5
Intestinal microbiome in scleroderma: recent progress.硬皮病的肠道微生物组：最新进展。
Curr Opin Rheumatol. 2017 Nov;29(6):553-560. doi: 10.1097/BOR.0000000000000429.
6
Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis.纤维化倾向自身免疫性疾病的一致微生物组特征：IgG4 相关疾病和系统性硬化症。
Genome Med. 2021 Feb 28;13(1):35. doi: 10.1186/s13073-021-00853-7.
7
Emerging pathogenic links between microbiota and the gut-lung axis.肠道菌群与肺肠轴之间新出现的致病联系。
Nat Rev Microbiol. 2017 Jan;15(1):55-63. doi: 10.1038/nrmicro.2016.142. Epub 2016 Oct 3.
8
Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease.肠道菌群失调在系统性硬化症中很常见，并与疾病的胃肠道和肠外特征相关。
Arthritis Res Ther. 2016 Nov 29;18(1):278. doi: 10.1186/s13075-016-1182-z.
9
Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.“一切疾病始于肠道”？微生物组中的肠道-器官交叉对话。
Appl Microbiol Biotechnol. 2024 May 21;108(1):339. doi: 10.1007/s00253-024-13180-9.
10
Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.益生菌对系统性硬化症胃肠道症状和免疫参数的影响：一项随机安慰剂对照试验。
Rheumatology (Oxford). 2019 Nov 1;58(11):1985-1990. doi: 10.1093/rheumatology/kez160.
引用本文的文献
1
The Relationship Between Microbiota, Nutrition, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis: A Systematic Review of the Literature.系统性硬化症患者微生物群、营养与胃肠道症状之间的关系：文献系统综述
Int J Mol Sci. 2025 Aug 8;26(16):7685. doi: 10.3390/ijms26167685.
2
Pathogenesis of systemic sclerosis: an integrative review of recent advances.系统性硬化症的发病机制：近期进展的综合综述
J Rheum Dis. 2025 Apr 1;32(2):89-104. doi: 10.4078/jrd.2024.0129. Epub 2024 Nov 28.
3
An international perspective on the future of systemic sclerosis research.系统性硬化症研究未来的国际视角。
Nat Rev Rheumatol. 2025 Mar;21(3):174-187. doi: 10.1038/s41584-024-01217-2. Epub 2025 Feb 14.
4
Gut microbiome and metabolomics in systemic sclerosis: feature, link and mechanisms.肠道微生物组和代谢组学在系统性硬化症中的特征、关联和机制。
Front Immunol. 2024 Nov 4;15:1475528. doi: 10.3389/fimmu.2024.1475528. eCollection 2024.
5
Deficiency and altered phenotype of mucosal-associated invariant T cells in systemic sclerosis.系统性硬化症中黏膜相关恒定T细胞的缺陷与表型改变
J Scleroderma Relat Disord. 2024 Feb;9(1):67-78. doi: 10.1177/23971983231209807. Epub 2023 Nov 23.
6
The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.系统性硬化症中的微生物组：发病机制与治疗潜力。
Int J Mol Sci. 2022 Dec 18;23(24):16154. doi: 10.3390/ijms232416154.
本文引用的文献
1
Longitudinal Characterisation of the Gastrointestinal Tract Microbiome in Systemic Sclerosis.系统性硬化症患者胃肠道微生物群的纵向特征分析
Eur Med J (Chelmsf). 2020 Dec 10;7:110-118. doi: 10.33590/emj/20-00043.
2
Regulation, risk and safety of Faecal Microbiota Transplant.粪便微生物群移植的监管、风险与安全性
Infect Prev Pract. 2020 Sep;2(3):100069. doi: 10.1016/j.infpip.2020.100069. Epub 2020 Jun 9.
3
Host variables confound gut microbiota studies of human disease.宿主变量会干扰人类疾病的肠道微生物组研究。
Nature. 2020 Nov;587(7834):448-454. doi: 10.1038/s41586-020-2881-9. Epub 2020 Nov 4.
4
Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study.霉酚酸酯治疗系统性硬化症：药物暴露表现出相当大的个体间差异——一项前瞻性、观察性研究。
Arthritis Res Ther. 2020 Oct 6;22(1):230. doi: 10.1186/s13075-020-02323-8.
5
Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.粪便微生物群移植治疗系统性硬化症：一项双盲、安慰剂对照随机先导试验。
PLoS One. 2020 May 21;15(5):e0232739. doi: 10.1371/journal.pone.0232739. eCollection 2020.
6
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification.在2019冠状病毒病大流行期间筛查粪菌移植供体：粪便严重急性呼吸综合征冠状病毒2病毒定量方案
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):642-643. doi: 10.1016/S2468-1253(20)30124-2. Epub 2020 Apr 22.
7
The microbiome in rheumatology: Where are we and where should we go?风湿学中的微生物组：我们在哪里，我们应该去哪里？
Ann Rheum Dis. 2020 Jun;79(6):727-733. doi: 10.1136/annrheumdis-2019-216631. Epub 2020 Apr 24.
8
The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks.肠道-肺部轴在健康与呼吸疾病中的作用：器官间和生物界间交流的场所。
Front Cell Infect Microbiol. 2020 Feb 19;10:9. doi: 10.3389/fcimb.2020.00009. eCollection 2020.
9
The microbiome in autoimmune rheumatic disease.自身免疫性风湿病中的微生物组。
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101473. doi: 10.1016/j.berh.2019.101473. Epub 2020 Feb 7.
10
The potential of fecal microbiota transplantation in systemic sclerosis.粪便微生物群移植在系统性硬化症中的潜力。
Expert Rev Clin Immunol. 2020 Feb;16(2):117-118. doi: 10.1080/1744666X.2019.1707665. Epub 2020 Jan 6.
Zotero 插件